Healthtech Solutions Inc. (HLTT) Stock Analysis
DELISTED 2025
What happened to Healthtech Solutions Inc. (HLTT) stock?
Healthtech Solutions Inc. (HLTT) no longer trades on public markets. It was delisted in November 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Healthtech Solutions Inc. (HLTT) trades at $0.0001. Healthtech Solutions Inc. focuses on developing wound care products and AI-based image analysis software. The company operates in the life sciences sector, targeting chronic wounds and diagnostic imaging. Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for HLTT: HLTT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HLTT against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
HLTT: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Healthtech Solutions Inc. (HLTT) Healthcare & Pipeline Overview
Healthtech Solutions Inc. is a life sciences company developing wound care products like AmnioBind and AI-driven imaging software for musculoskeletal and cardiac applications. Operating in the healthcare information services sector, the company aims to improve treatment outcomes through innovative technologies, but faces challenges inherent to OTC-listed, early-stage ventures.
What Is the Investment Thesis for HLTT?
Healthtech Solutions Inc. presents a high-risk, high-reward investment opportunity. The company's focus on innovative wound care and AI-driven diagnostics addresses significant market needs. AmnioBind, if successfully commercialized, could capture a share of the growing wound care market. The AI-based imaging software offers potential for improved diagnostic accuracy and efficiency. However, the company's OTC listing, negative profitability (Profit Margin: -180.3%), and small market capitalization ($0.00B) indicate substantial risks. Key catalysts include successful clinical trials, regulatory approvals, and strategic partnerships. The investment thesis hinges on the company's ability to navigate the regulatory landscape and secure funding to support its development programs. The high Beta of 1.95 suggests high volatility.
Based on FMP financials and quantitative analysis
HLTT Key Highlights
Gross Margin of 92.7% indicates strong potential profitability if sales volume increases.
- Focus on AmnioBind, a placental membrane allograft, targets a growing market for advanced wound care.
- Development of AI-based image analysis software positions the company in the rapidly expanding field of medical imaging.
- Based in the US, allowing for direct access to one of the largest healthcare markets.
- Operating with a small team of 18 employees, indicating a lean operational structure.
Who Are HLTT's Competitors?
HLTT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CMHSF Comprehensive Healthcare Systems, Inc. | $0.31 | +0.00% | $5.62M | 55 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| CMPD CompuMed, Inc. | $7.86 | +16.44% | $10.1M | 60 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
| THKKF Think Research Corporation | $0.23 | -1.74% | $17.8M | 57 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | 67 |
| AIRDF Rocket Doctor AI Inc. | $0.44 | -2.99% | $42.4M | 56 |
| VRHI Veri Medtech Holdings Inc. | $2.35 | +0.00% | $46.9M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HLTT's Key Strengths?
Innovative wound care technology (AmnioBind).
- AI-based image analysis software development.
- Focus on regenerative medicine.
- Potential for novel cardiac treatment technology.
What Are HLTT's Weaknesses?
OTC listing indicates higher risk.
- Negative profitability and small market capitalization.
- Limited operating history.
- Dependence on regulatory approvals.
What Could Drive HLTT Stock Higher?
Clinical trial results for AmnioBind in treating diabetic foot ulcers.
- Regulatory approvals for AI-based image analysis software.
- Strategic partnerships with hospitals and clinics.
- Expansion into new wound care applications.
- Development of the curative waveform technology for heart rhythm correction.
What Are the Key Risks for HLTT?
Financial-distress signal — its Altman Z-Score of -11.96 sits in the distress zone (elevated bankruptcy risk).
- Competition from established medical device companies.
- Regulatory hurdles and delays.
- Funding constraints and dependence on securing additional capital.
- Technological obsolescence.
- OTC listing indicates higher risk and limited liquidity.
What Are the Growth Opportunities for HLTT?
- Healthtech Solutions can expand AmnioBind's application to treat various types of chronic wounds, including pressure ulcers and surgical wounds. This expansion requires further clinical trials and regulatory approvals, but could significantly increase the product's market potential. Timeline: Ongoing.
- Development and commercialization of AI-based diagnostic tools: The market for AI in healthcare is projected to experience substantial growth in the coming years. Healthtech Solutions can capitalize on this trend by developing and commercializing its AI-based image analysis software for chest and musculoskeletal systems. This requires further development, validation, and regulatory clearance. Timeline: 2-3 years.
- Strategic partnerships with hospitals and clinics: Collaborating with healthcare providers can accelerate the adoption of Healthtech Solutions' products and technologies. Partnerships can provide access to patient populations, clinical data, and distribution channels. These partnerships can also facilitate the integration of the company's solutions into existing healthcare workflows. Timeline: Ongoing.
- Geographic expansion into international markets: The global market for wound care and diagnostic imaging is vast. Healthtech Solutions can expand its reach by entering international markets, such as Europe and Asia. This requires adapting its products and technologies to meet local regulatory requirements and market needs. Timeline: 3-5 years.
- Development of the curative waveform technology for heart rhythm correction: The company's software technology that compares a healthy heart rhythm electronic signal with a damaged heart's signal to derive an electronic signal representing the curative waveform has the potential to revolutionize cardiac treatment. Further research, development, and clinical trials are needed to validate this technology. Timeline: 5+ years.
What Are HLTT's Competitive Advantages?
- Proprietary AmnioBind technology with potential for strong efficacy in wound healing.
- AI-based image analysis software offering improved diagnostic accuracy.
- Focus on innovative solutions in regenerative medicine and medical imaging.
- Potential for patent protection on key technologies.
What Does HLTT Do?
Founded in 2018 and based in Tuckahoe, New York, Healthtech Solutions Inc. operates as a life sciences company focused on developing and commercializing innovative healthcare solutions. The company's primary focus is on wound care products, particularly for acute and chronic wounds. Their lead product, AmnioBind, is a placental membrane allograft designed to treat burns and non-healing wounds, such as diabetic foot ulcers. This technology leverages the regenerative properties of placental tissue to promote faster and more effective wound healing. In addition to wound care, Healthtech Solutions is developing ultrasound imaging and artificial intelligence-based image analysis software. These technologies are intended for use in the treatment of chest and musculoskeletal systems, enabling more accurate and efficient diagnoses. The company is also working on software technology that analyzes heart rhythm electronic signals to derive a curative waveform, potentially offering a novel approach to cardiac treatment. Healthtech Solutions operates through its subsidiaries, managing all aspects of product development, manufacturing, and commercialization. As a relatively young company, it is still in the early stages of market penetration and faces the challenges of establishing its brand and securing regulatory approvals. The company's small size, with 18 employees, reflects its current stage of development and its focus on research and development activities.
What Products and Services Does HLTT Offer?
- Develops AmnioBind, a placental membrane allograft for treating burns and non-healing wounds.
- Creates ultrasound imaging software for chest and musculoskeletal system applications.
- Develops AI-based image analysis software to aid in medical diagnoses.
- Researches software technology to derive a curative waveform for heart rhythm correction.
- Focuses on regenerative medicine and advanced diagnostic technologies.
- Operates through subsidiaries to manage product development and commercialization.
How Does HLTT Make Money?
- Develops and commercializes wound care products.
- Licenses or sells AI-based diagnostic software.
- Generates revenue through product sales and licensing agreements.
- Focuses on innovation in regenerative medicine and medical imaging.
What Industry Does HLTT Operate In?
Healthtech Solutions operates within the healthcare information services and medical devices industry, a sector characterized by rapid innovation and increasing demand for advanced technologies. The wound care market is driven by the rising prevalence of chronic diseases such as diabetes, which leads to non-healing ulcers. The market for AI-based diagnostic tools is also expanding rapidly, fueled by the need for more accurate and efficient diagnostic methods. Competition includes established medical device companies and emerging biotech firms. Healthtech Solutions aims to differentiate itself through its focus on placental-derived therapies and AI-driven solutions.
Who Are HLTT's Key Customers?
- Hospitals and clinics using wound care products.
- Medical professionals treating chronic wounds.
- Radiologists and imaging specialists.
- Healthcare providers seeking advanced diagnostic tools.
Company Profile
Healthtech Solutions Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Tuckahoe, US. The company is led by CEO James Pesoli. HLTT has traded publicly since 2006.
Financial Health
Healthtech Solutions Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -11.96 places it in the distress zone, a signal of elevated financial risk.
HLTT Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates strong confidence from executives in the company's future prospects.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could disrupt the market.
- Healthtech Solutions has been gaining attention for its strategic partnerships, enhancing its market position and credibility.
- The overall healthcare sector is experiencing growth, and HLTT is well-positioned to capitalize on this trend.
Bear Case
- There are concerns about the company's ability to scale operations effectively, which could hinder growth potential.
- Recent social sentiment has shown skepticism regarding the sustainability of HLTT's recent gains, with some traders expressing caution.
- Increased competition in the healthtech space could pressure HLTT's market share and profitability.
- Some analysts are worried about regulatory challenges that could impact the company's product rollout and market entry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HLTT Latest News
No recent news available for HLTT.
Leadership: James Pesoli
CEO
James Pesoli serves as the CEO of Healthtech Solutions Inc., leading a team of 18 employees. Information regarding his detailed career history, educational background, and previous roles is not available. His leadership is focused on guiding the company's strategic direction and overseeing the development and commercialization of its healthcare technologies.
Track Record: Due to limited information, it is difficult to assess James Pesoli's specific achievements and strategic decisions at Healthtech Solutions Inc. However, as CEO since 2018, he has overseen the company's efforts to develop AmnioBind and AI-based diagnostic tools.
HLTT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Healthtech Solutions Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to listed securities.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in Healthtech Solutions Inc.
- Lower liquidity can lead to price volatility and difficulty in executing trades.
- OTC listing may indicate a higher risk of fraud or mismanagement.
- The company may not meet the listing requirements of major exchanges.
- Dependence on securing additional funding to support operations.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the market potential for the company's products and technologies.
- Evaluate the company's competitive position within the industry.
- Determine the company's cash runway and funding needs.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC-listed stocks.
- Development of innovative wound care technology (AmnioBind).
- Focus on AI-based diagnostic software.
- Presence in the healthcare sector, which is subject to regulatory oversight.
- Company has been in operation since 2018.
- Management team is actively working to develop and commercialize products.
Common Questions About HLTT (Healthcare)
What happened to Healthtech Solutions Inc. (HLTT) stock?
Healthtech Solutions Inc. (HLTT) no longer trades on public markets. It was delisted in November 2025. The figures below are historical and are not a current quote.
Can I still buy HLTT shares?
No. HLTT stopped trading on public markets in November 2025, so the shares are not available through a broker. Anything you see quoted for HLTT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before HLTT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Healthtech Solutions Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Healthtech Solutions Inc. do?
Healthtech Solutions Inc. is a life sciences company focused on developing and commercializing innovative healthcare solutions. Their primary focus is on wound care products, particularly AmnioBind, a placental membrane allograft designed to treat burns and chronic wounds like diabetic foot ulcers. Additionally, they are developing AI-based image analysis software for diagnostic applications and exploring novel cardiac treatment technologies.
What do analysts say about HLTT stock?
Currently, there is no available analyst coverage for Healthtech Solutions Inc. due to its OTC listing and small market capitalization. Therefore, no consensus estimates or price targets are available. Investors should conduct their own thorough research and due diligence before making any investment decisions, considering the inherent risks associated with OTC-listed companies and the lack of analyst opinions.
What are the main risks for HLTT?
The main risks for Healthtech Solutions Inc. include its OTC listing, which indicates higher risk and limited liquidity. The company's negative profitability and small market capitalization also pose financial challenges. Regulatory hurdles and competition from established medical device companies are additional concerns. Furthermore, the company's dependence on securing additional funding and the potential for technological obsolescence represent significant risks to its long-term success.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company due to its OTC listing and small market capitalization.
- Financial data is based on available information and may not be comprehensive.
- AI analysis is pending and may provide further insights in the future.